Napo Pharmaceuticals, Inc. Files for MUMS Designation for Crofelemer for Chemotherapy Induced Diarrhea in Dogs
SAN FRANCISCO--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc. (“Napo”) announced it had applied for a Minor Use in a Major Species (“MUMS”) designation for crofelemer, for use in chemotherapy induced diarrhea in dogs – (“CID”). Crofelemer is also the subject of a pending New Drug Application (“NDA”) for use in humans for the indication of chronic diarrhea in people living with HIV/AIDS.